Madison Avenue Partners discloses 5.31% stake in Lakefront Biotherapeutics

Madison Avenue Partners disclosed on June 15, 2026, that it crossed the 5% voting rights threshold in Lakefront Biotherapeutics. As of June 24, the firm held 3,498,892 voting rights, representing a 5.31% stake in the company's 65,897,071 outstanding shares. The position consists solely of direct voting rights with no associated financial instruments.

Madison Avenue Partners disclosed it crossed the 5% voting rights threshold in Lakefront Biotherapeutics on June 15, 2026. * It held 3,498,892 voting rights as of June 24, equal to 5.31% of 65,897,071 outstanding shares. * The position was reported as direct voting rights only, with no equivalent financial instruments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606291601OMX___EUPRNL_GNW1001210242_nl) on June 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)